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Abstract 
Background: Single low-dose primaquine (SLD-PQ) is recommended in combination with artemisinin-based combi-
nation therapy to reduce Plasmodium falciparum transmission in areas threatened by artemisinin resistance or aiming 
for malaria elimination. SLD-PQ may be beneficial in mass drug administration (MDA) campaigns to prevent malaria 
transmission but uptake is limited by concerns of hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient 
individuals. The aim of this study was to improve the evidence on the safety of MDA with SLD-PQ in a sub-Saharan 
African setting.
Methods: A nonlinear mixed-effects model describing the pharmacokinetics and treatment-induced hemolysis 
of primaquine was developed using data from an adult (n = 16, G6PD deficient) and pediatric study (n = 38, G6PD 
normal). The relationship between primaquine pharmacokinetics and hemolysis was modeled using an established 
erythrocyte lifespan model. The safety of MDA with SLD-PQ was explored through Monte Carlo simulations for 
SLD-PQ at 0.25 or 0.4 mg/kg using baseline data from a Tanzanian setting with detailed information on hemoglobin 
concentrations and G6PD status.
Results: The predicted reduction in hemoglobin levels following SLD-PQ was small and returned to pre-treatment 
levels after 25 days. G6PD deficiency (African A- variant) was associated with a 2.5-fold (95% CI 1.2–8.2) larger reduc-
tion in hemoglobin levels. In the Tanzanian setting where 43% of the population had at least mild anemia (hemo-
globin < 11–13 g/dl depending on age and sex) and 2.73% had severe anemia (hemoglobin < 7–8 g/dl depending 
on age and sex), an additional 3.7% and 6.0% of the population were predicted to develop at least mild anemia and 
0.25% and 0.41% to develop severe anemia after 0.25 and 0.4 mg/kg SLD-PQ, respectively. Children < 5 years of age 
and women ≥ 15 years of age were found to have a higher chance to have low pre-treatment hemoglobin.
Conclusions: This study supports the feasibility of MDA with SLD-PQ in a sub-Saharan African setting by predicting 
small and transient reductions in hemoglobin levels. In a setting where a substantial proportion of the population had 
low hemoglobin concentrations, our simulations suggest treatment with SLD-PQ would result in small increases in 
the prevalence of anemia which would most likely be transient.
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Background
The annual number of malaria cases is estimated at 228 
million, most of them in sub-Saharan Africa [1]. Plas-
modium falciparum is the main malaria species in this 
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region. The transmission of malaria depends on the 
presence of sexual stage parasites, or gametocytes. Pri-
maquine is the only currently available drug target-
ing mature Plasmodium falciparum gametocytes. To 
decrease transmission and limit development of arte-
misinin resistance, a single low dose of primaquine 
(SLD-PQ) is recommended by the World Health Organi-
zation (WHO) in combination with an artemisinin-based 
combination therapy [1–3]. As artemisinin resistance 
is emerging in sub-Saharan Africa, strategies that could 
limit resistance are much needed [4]. However, concerns 
using SLD-PQ exist because of the risk of hemolysis, 
especially in individuals with (severe forms of ) glucose-
6-phosphate dehydrogenase (G6PD) deficiency [2, 5, 6]. 
Primaquine-induced hemolysis may predominantly be 
driven by cytochrome P450 D6 (CYP2D6)-mediated 
metabolites [7–9].
The WHO recommends mass drug administra-
tion (MDA) for interruption of transmission in areas 
approaching elimination with good access to treatment 
and surveillance [1]. MDA consists of treating a defined 
population in a certain area at approximately the same 
time with therapeutic doses of an antimalarial. SLD-PQ 
at 0.25 mg per kg body weight is recommended for MDA 
targeting Plasmodium falciparum malaria [10]; this dose 
is considered safe even for G6PD-deficient individu-
als, and the WHO recommends it may be administered 
without testing for G6PD deficiency [2, 11–13]. How-
ever, most of the studies that assessed safety have been 
performed in small populations with relatively high pre-
treatment hemoglobin levels. Moreover, pragmatic dos-
ing strategies may result in some individuals receiving a 
higher dose than the recommended 0.25  mg/kg, which 
may achieve better gametocyte clearance but potentially 
increase the risk of hemolysis [14–16]. If co-administered 
with dihydroartemisinin-piperaquine (DP) instead of 
artemether-lumefantrine (AL), it may even be needed to 
use a target dose of 0.4 mg/kg to achieve the same level 
of gametocyte clearance [16]. This leaves the question 
whether some populations would still be at risk of clini-
cally relevant hemolysis when SLD-PQ is used at popula-
tion level. The aim of this study was, therefore, to predict 
the safety of SLD-PQ when used in MDA campaigns in 




Table  1 shows the characteristics of the participants 
included in the two studies who provided pharmacoki-
netic data [11, 12]. The first study was a randomized 
placebo-controlled trial in children from Balonghin, Bur-
kina Faso [11]. The purpose of the study was to assess 
the effect of SLD-PQ (0.25 and 0.4 mg/kg) on the trans-
mission of malaria. The study included Plasmodium 
falciparum-infected children aged 2–15  years without 
any malaria symptoms and normal G6PD activity. The 
children were treated with AL alone, AL and 0.25 mg/kg 
primaquine, or AL and 0.40 mg/kg primaquine. AL was 
given twice daily for 3 days, and primaquine or placebo 
was administered with the fifth dose of AL. A subset of 
40 children was included in a pharmacokinetic sub-study. 
One blood sample was taken pre-dose, four in the first 
12 h and two between 24 and 72 h after dosing. Hemo-
globin concentrations were quantified using a HemoCue 
photometer (HemoCue AB, Angelholm, Sweden) on days 
0 (pre-dosing), 2, 3, 7, 10 and 14. Two of the 40 children 
were excluded because of undeterminable primaquine 
concentrations. In total, 228 pharmacokinetic samples 
and 226 hemoglobin samples from 38 children were 
included in the analysis.
The second study was an open-label, randomized, 
dose-escalation trial in G6PD-deficient (African A- vari-
ant) adult males from Burkina Faso and The Gambia 
[12]. The purpose of the study was to assess the safety of 
SLD-PQ (0.25  mg/kg and 0.4  mg/kg) in G6PD-deficient 
Table 1 Characteristics of the populations included in the 
analysis
a Original data from Goncalves et al [11]. bOriginal data from Bastiaens et al. 
[12].  AS: activity score; BLQ: below limit of quantification; CYP2D6: cytochrome 
P450 D6; Hb: hemoglobin
Characteristic Pediatrica Adultb 
Number of patients 38 16
G6PD deficient No Yes
Males, % 42.1 100
P. falciparum infected, % 100 69
Number treated with 0.25 mg/kg pri-
maquine
18 10
Number treated with 0.4 mg/kg pri-
maquine
20 6
Age in years, median (range) 9.5 (2–14) 24.5 (13–44)
Weight in kg, median (range) 23.3 (12.1–43.5) 55.4 (29.9–76.4)
Baseline Hb in g/dl, median (range) 11.7 (9.3–13.8) 13.1 (12–15.4)
Number of pharmacokinetic samples 228 97
Pharmacokinetic data BLQ, % 14.2 25.2
Number of Hb samples 226 199
CYP2D6 AS distribution, n (%)
 0 1 (2.63) 0 (0)
 0.5 4 (10.5) 4 (25)
 1 6 (15.8) 1 (6.25)
 1.5 13 (34.2) 7 (43.75)
 2 7 (18.4) 3 (18.75)
 3 3 (7.89) 0 (0)
 Missing 4 (10.5) 1 (6.25)
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African males. All individuals from Burkina Faso and 
some from The Gambia were Plasmodium falciparum 
malaria infected and asymptomatic. The participants 
were treated either with AL (Burkina Faso) or DP (The 
Gambia) alone or in combination with primaquine. Six 
pharmacokinetic samples were taken up to 72 h post dose 
from 16 participants. Randomized sampling times were 
allocated so that there were four samples on day 0 (day 
of dosing) and one each on days 1 and 2 per individual. 
Hemoglobin concentrations were assessed on day 0 (pre-
dosing), twice daily on days 1, 2 and 3, and once daily on 
days 4, 5, 7, 10, 14 and 28 using self-calibrating HemoCue 
201+ photometers (HemoCue AB, Angelholm, Sweden). 
From this second study, 97 pharmacokinetic samples and 
199 hemoglobin samples were included in the analysis.
Quantification of primaquine and genotyping of G6PD 
and CYP2D6
Primaquine plasma levels were quantified using liquid 
chromatography-mass spectrometry at two different 
laboratories as previously described with lower limits 
of quantification of 4 ng/ml and 1.14 ng/ml for the first 
and second study, respectively [12, 17, 18]. For the first 
study, G6PD status was determined using the BinaxNow 
rapid diagnostic test (Alere Inc., Waltham, MA, USA) as 
described in the original publication [11]. For the second 
study, G6PD status was determined using Beutler’s fluo-
rescence spot test (R&D Diagnostics, Greece) [12]. For 
both studies, CYP2D6 genotype was determined with 
Quantstudio 12K Flex OpenArray with TaqMan assays 
(Thermo Fisher Scientific, Waltham, MA, USA) [12, 18].
Pharmacokinetic/pharmacodynamic modeling
The analysis of the pharmacokinetic data and the rela-
tionship with hemoglobin concentrations over time was 
performed by means of nonlinear mixed-effects mod-
eling. Model structure and estimates of previous work 
on the pediatric dataset were used as a starting point for 
the pharmacokinetic analysis [18]. Three transit compart-
ments described the gradual absorption of primaquine. 
The model incorporated a well-stirred liver model [19]. 
Liver volume was calculated from total body weight and 
height [20]. A liver plasma flow of 49.5 l/h was assumed, 
derived from an adult total blood flow of 90 l/h and a 
plasma fraction of 55% in whole blood (hematocrit level 
45%). Allometric scaling to a total body weight of 70 kg 
for volume, clearance and liver plasma flow param-
eters was included to account for differences in weight, 
with exponents of respectively 1 and 0.75 for volume 
and clearance parameters [21]. The bioavailability of 
primaquine was assumed to be 100%, and all estimated 
parameters are apparent oral pharmacokinetic param-
eters. Primaquine pharmacokinetic data below the limit 
of quantification were handled using the M3 method as 
described by Beal et al. [22].
CYP2D6 activity score (AS), a quantitative measure of 
phenotype, was inferred from the CYP2D6 genotype [23, 
24]. The AS value for an individual can be, going from no 
to high activity, 0, 0.5, 1, 1.5, 2 or 3. The CYP2D6 AS was 
included as a covariate on the CYP2D6-mediated clear-
ance. Quantification of the CYP2D6-mediated metabo-
lites is difficult, and no usable pharmacokinetic data were 
available [21]. The same relationship between AS and 
CYP2D6-mediated clearance as in the model built on 
the pediatric data was included in the current model as 
alternative relationships could not be explored because of 
the lack of data on these metabolites [18]. The individual 
CYP2D6-mediated clearance was calculated as follows:
where the  CLCYP2D6,population is the estimated population 
CYP2D6-mediated clearance, AS is the CYP2D6 activity 
score, and WT is the total body weight. Missing CYP2D6 
AS (11% in the pediatric study and 7% in the adult study) 
was imputed with the most prevalent score of 1.5. As 
no pharmacokinetic data on the CYP2D6-mediated 
metabolites were used, it was decided a priori that a sin-
gle compartment with volume and clearance parameters 
fixed to 1 would describe the pharmacokinetics of the 
CYP2D6-mediated metabolites. The metabolite compart-
ment describes a virtual CYP2D6-dependent metabolite 
concentration, expressed as arbitrary unit per milliliter. 
Carboxyprimaquine and other metabolites of primaquine 
were not described by the model.
The pharmacodynamic model was developed fol-
lowing the pharmacokinetic model, using individual 
pharmacokinetic parameter estimates as input. The 
relationship between primaquine metabolite concentra-
tions and hemolysis was modeled using an established 
erythrocyte lifespan model [25]. The erythrocyte lifespan 
model, shown in the lower half of Fig.  1, included four 
transit compartments and a concentration-slope effect 
describing the elimination of erythrocytes following 
primaquine-induced hemolysis caused by the CYP2D6-
mediated metabolites. As hemoglobin is directly corre-
lated with erythrocyte count, all lifespan compartments 
together make up the total hemoglobin value for an indi-
vidual. The effect of G6PD deficiency on the primaquine-
induced hemolysis was described by estimating a scaling 
factor on the concentration-slope effect. The primaquine-
induced hemolysis (elimination of erythrocytes − Keryth-
rocyte elimination) was calculated as follows:





Kerythrocyte elimination = CCYP2D6 metabolites · Slope · FG6PDd
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where CCYP2D6 metabolites is the concentration in the 
CYP2D6-mediated metabolite compartment, Slope is the 
concentration-slope effect of primaquine-induced elimi-
nation of erythrocytes, and FG6PDd is the factor by which 
the primaquine-induced elimination of erythrocytes is 
increased in G6PD-deficient individuals.
Inter-individual variability in the pharmacokinetic and 
pharmacodynamic parameters was assumed to be log-
normally distributed. Residual variability in primaquine 
pharmacokinetics was implemented using a propor-
tional error model in addition to an additive residual 
error which was fixed to 50% of the largest of the two 
lower limit of quantification values, in line with the M3 
method by Beal [22]. For the pharmacodynamic model, 
additive, proportional and combined models were tested 
to describe the residual variability. The relative standard 
errors of the pharmacokinetic and pharmacodynamic 
parameters were derived from a non-parametric boot-
strap with 1000 samples.
Mass drug administration simulations
The developed model was used to explore the safety of 
MDA with SLD-PQ in a sub-Saharan African setting 
through Monte Carlo simulations. For this, we selected 
a large cross-sectional Tanzanian dataset that included 
data on age, sex, weight, hemoglobin level (g/dl) and 
G6PD status to create a simulation dataset [26, 27]. G6PD 
deficiency in this population was defined by having the 
hemizygous or homozygous G202A/A376G genotype, 
characterizing the G6PD A- variant. Children < 6 months 
old were removed from the dataset since we assumed 
they would not be included in MDA as primaquine is 
contraindicated for children < 6 months old and pregnant 
women [10]. The total number of individuals was 7672 
after exclusion of children < 6 months old and individu-
als with missing data (568 individuals were removed). 
Each individual was included four times in the simulation 
dataset to include more combinations of CYP2D6 status 
and to assess the effect of inter-individual variability bet-
ter. CYP2D6 AS was randomly assigned to the sampled 
individuals according to distributions described in the 
literature, resulting in probabilities of 0.026, 0.101, 0.256, 
0.386, 0.209 and 0.022 for an AS of 0, 0.5, 1, 1.5, 2 and 3, 
respectively [28, 29].
Hemoglobin nadir was simulated for a single dose 
of 0.25  mg/kg or 0.4  mg/kg primaquine. We simu-
lated doses assuming that the smallest available tablet 
size of primaquine is 2.5  mg and that it can be split in 
two (administered doses are rounded to 1.25  mg incre-
ments). The predicted prevalence of different severity 
classes of anemia at the nadir was assessed as a measure 
of safety. The severity classes of anemia consisted of mild, 
moderate and severe anemia and their definitions were 
adapted from the WHO [30]. Depending on age, sex and 
Fig. 1 Schematic of the final pharmacokinetic/pharmacodynamic model. The pharmacokinetic model is on the upper half of the figure and the 
pharmacodynamic model on the lower half. CCYP2D6: concentration in the CYP2D6-mediated metabolite compartment;  CLH1: hepatic clearance out 
of the system;  CLH2: CYP2D6-mediated hepatic clearance;  CLm: clearance of the metabolite; CYP2D6: cytochrome P450 D6; EH: hepatic extraction 
ratio; FG6PDd: factor by which the primaquine-induced elimination of erythrocytes is increased in G6PD-deficient individuals; Hb: hemoglobin; Kin: 
erythrocyte production; Kerythrocyte elimination: primaquine-induced elimination of erythrocytes; Ktr: first-order rate constant defined as 4/LS where LS 
is the erythrocyte lifespan in hours; MAT: mean absorption time; PD: pharmacodynamic; PK: pharmacokinetic; Slope: concentration-slope effect 
of primaquine-induced elimination of erythrocytes; VL: liver volume; Vm: volume of the metabolite compartment; VPQ: volume of the primaquine 
compartment
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pregnancy status, the WHO definitions described indi-
viduals with hemoglobin levels < 11–13  g/dl as mildly 
anemic, individuals with hemoglobin levels < 7–11  g/dl 
as moderately anemic and individuals with hemoglobin 
levels < 7–8 g/dl as severely anemic. The complete defi-
nitions by age, sex and pregnancy status can be found in 
the supplementary materials (Additional file 1: Table S1).
We also explored whether the incidence of severe 
anemia could be limited by excluding individuals with 
pre-treatment hemoglobin levels below a certain thresh-
old from dosing. Based on the hemoglobin distribution 
within the simulation dataset, we assessed scenarios 
where individuals with hemoglobin levels < 7, 7.5 and 
8 g/dl were not treated with primaquine.
Software, parameter estimation and model selection
R version 3.4.3 was used for data management, statistics 
and plotting [31]. Model development was performed 
using the nonlinear mixed-effects modeling program 
NONMEM version 7.4 with Pirana as an interface [32, 
33]. PsN version 4.7 was used as an aid for advanced 
functionalities [33]. The Xpose4 R package version 4.6.1 
was used for graphical visualization of the visual predic-
tive checks (VPCs) [33]. The VPCs were performed using 
1000 simulations and were prediction and variability cor-
rected [34].
In NONMEM, the Laplacian method with interaction 
was used for estimation of the pharmacokinetic parame-
ters [35]. For estimation of the pharmacodynamic param-
eters, the first-order conditional estimation method with 
interaction was used. Goodness-of-fit plots together with 
differences in objective function value were used to com-
pare performances between different models. A change 
in objective function value of > 3.84 between two nested 
models was considered statistically significant (p < 0.05) 
for 1 degree of freedom.
Results
Pharmacokinetic modeling
Figure  1 shows the model schematic of both the phar-
macokinetic and pharmacodynamic models, with the 
pharmacokinetic model shown in the upper half. The 
pharmacokinetic model for primaquine in children was 
successfully extended to adults by means of allometric 
scaling of the pharmacokinetics on body weight and re-
estimation of the parameters. The estimated pharma-
cokinetic parameters and their uncertainty are shown 
in Table  2. Inter-individual variability was included on 
the central volume of primaquine, mean absorption 
time and clearance. Both the CYP2D6-mediated hepatic 
clearance and hepatic clearance out of the system share 
the same inter-individual variability. The VPC, good-
ness-of-fit plots and model code are included within the 
supplemental information (Additional file  2: Figure S1, 
Additional file 3: Figure S2 and Additional file 5: Model 
code).
Pharmacodynamic modeling
The erythrocyte lifespan model schematic is shown in 
the lower half of Fig.  1. One concentration-slope effect 
describing the primaquine-induced elimination of eryth-
rocytes was estimated for all four lifespan compartments, 
as we did not have data on erythrocyte populations with 
different ages. A lifespan of 276  h (95% CI 119–654  h) 
was estimated for both the G6PD-normal and -deficient 
individuals; separate lifespans for G6PD-normal and 
-deficient individuals could not be estimated reliably. The 
effect of G6PD deficiency on the primaquine-induced 
elimination of erythrocytes was estimated at a 2.46-fold 
increase (95% CI 1.16–8.17-fold). A proportional error 
model was most appropriate to describe the residual 
error in the pharmacodynamic model. The pharmaco-
dynamic parameters and their uncertainty are shown in 
Table 2. The VPC, goodness-of-fit plots and model code 
are included within the supplemental materials (Addi-
tional file  2: Figure S1, Additional file  4: Figure S3 and 
Additional file 5: Model code).
The predicted reduction in hemoglobin levels for a typ-
ical individual (weight 70 kg, length 170 cm, AS 1.5) with 
Table 2 Final pharmacokinetic and pharmacodynamic model 
parameters
CCYP2D6: concentration in the compartment for CYP2D6-mediated metabolites; 
 CLH1: hepatic clearance out of the system; CLH2: CYP2D6-mediated hepatic 
clearance; CV: coefficient of variation; FG6PDd: factor by which the primaquine-
induced elimination of erythrocytes is increased in G6PD-deficient individuals; 
IIV: inter-individual variability; MAT: mean absorption time; RSE: relative standard 
error; Slope: concentration-slope effect of primaquine-induced elimination of 
erythrocytes; VPQ: volume of distribution for primaquine
+ As derived from a non-parametric bootstrap with 1000 samples
# Both  CLH1 and  CLH2 share the same inter-individual variability
a Parameter was fixed during parameter estimation
Parameter Estimate RSE+, CV%
VPQ, l (70 kg) 130 6.05
CLH1, l/h (70 kg) 25.1 8.78
CLH2, l/h (70 kg) 5.6 29.6
MAT, h 0.915 11.2
IIV  CL#, CV% 46 30.6
IIV VPQ, CV% 44 26.5
IIV MAT, CV% 55 28.8
Proportional error, % 25.3 20.0
Additive error, ng/mla 2 –




Proportional error Hb, V% 6.95 4
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a baseline hemoglobin concentration of 13 g/dl, with and 
without G6PD deficiency following a single 0.25  mg/kg 
dose, is shown in Fig. 2. For a typical G6PD normal indi-
vidual, the reduction in hemoglobin from baseline to the 
nadir is approximately 0.13 g/dl. For a typical G6PD-defi-
cient individual, this reduction is 0.30 g/dl. It is predicted 
to take about 25 days for the hemoglobin concentration 
to return completely to pre-treatment values.
Mass drug administration simulations
The median (range) of hemoglobin was 12.1 (2.0–18.8) g/
dl and prevalence of G6PD deficiency was 5.51% in the 
simulation population. Following the linear kinetics of 
primaquine, the expected maximum concentration and 
total exposure following 0.4  mg/kg primaquine are 60% 
higher compared to 0.25  mg/kg primaquine. Table  3 
shows the predicted median reduction in hemoglobin 
levels at the nadir after 0.25  mg/kg and 0.4  mg/kg pri-
maquine for the whole population and by G6PD status. A 
table showing the predicted median reduction in hemo-
globin levels by CYP2D6 AS group is included in the sup-
plemental materials (Additional file 6: Table S2).
Table 4 shows the prevalence and grade of anemia after 
taking 0.25 mg/kg and 0.4 mg/kg primaquine. The preva-
lence of anemia without any intervention was already 
high (43.0%) in this population and even higher (49.6%) 
for the G6PD-deficient individuals. After SLD-PQ of 
0.25  mg/kg, an additional 3.7% of the general popula-
tion was predicted to develop anemia (8.6% relative 
increase from pre-treatment prevalence) and an addi-
tional 0.25% to develop severe anemia specifically (9.2% 
relative increase from pre-treatment prevalence). Follow-
ing a dose of 0.4 mg/kg primaquine, an additional 6.0% of 
the general population was predicted to develop anemia 
(14% relative increase from pre-treatment prevalence) 
and an additional 0.41% to develop severe anemia (15% 
relative increase from pre-treatment prevalence).
Fig. 2 Predicted reduction in hemoglobin levels after a single dose of 0.25 mg/kg primaquine for a typical G6PD-normal and -deficient individual. A 
typical individual was assumed to have a weight of 70 kg, length of 170 cm, CYP2D6 activity score of 1.5 and pre-treatment hemoglobin of 13 g/dl
Table 3 Predicted median reduction in hemoglobin after 0.25 
and 0.4 mg/kg primaquine






90% prediction interval 
of reduction in Hb, g/dla
All 0.25 0.16 0.054–0.32
0.4 0.26 0.088–0.51
G6PD normal 0.25 0.16 0.053–0.28
0.40 0.25 0.086–0.45
G6PD deficient 0.25 0.35 0.12–0.65
0.4 0.56 0.21–1.0
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The simulated hemoglobin distribution before treat-
ment and following 0.25 and 0.4  mg/kg primaquine for 
children < 5 years of age is depicted in Fig. 3. The hemo-
globin distributions for the other subgroups used in the 
anemia definition of the WHO are shown in the sup-
plementary information (Additional file  7: Figure S4). 
Changes in the distribution of hemoglobin levels after 
SLD-PQ are minimal. Children < 5  years of age and 
women ≥ 15 years of age have a relatively high propor-
tion of individuals near to and below the cut-off defining 
severe anemia both before and after treatment.
Excluding individuals with a pre-treatment hemo-
globin value < 7, 7.5 or 8  g/dl translates into excluding 
1.67%, 2.35% and 3.35% of the population, respectively 
(Additional file  8: Figure S5). Depending on the thresh-
old, 41–48% of the excluded individuals are < 5 years of 
age compared to 26% in the general population. Table 5 
shows the predicted prevalence of severe anemia after 
dosing with 0.25  mg/kg or 0.4  mg/kg primaquine by 
exclusion according to different pre-treatment hemo-
globin values. For a primaquine dose of 0.25 mg/kg, the 
proportion of individuals transitioning from moderate 
Table 4 Predicted prevalence of anemia and its severity after 0.25 and 0.4 mg/kg primaquine





(Hb > 11–13 g/
dl), %
All anemia grades 
(Hb < 11–13 g/dl), %
Mild anemia (Hb 7–11 
to 11–13 g/dl), %
Moderate anemia (Hb 
7–8 to 7–11 g/dl), %
Severe anemia 
(Hb < 7–8 g/
dl), %
All 0 57.0 43.0 18.3 22.0 2.73
0.25 53.3 46.7 19.6 24.1 2.98
0.40 51.0 49.0 20.1 25.7 3.14
G6PD normal 0 57.4 42.6 18.2 21.7 2.73
0.25 54.1 45.9 19.3 23.7 2.95
0.40 52.0 48.0 19.8 25.1 3.09
G6PD deficient 0 50.4 49.6 19.8 27.1 2.72
0.25 40.5 59.5 24.2 31.9 3.43
0.40 34.8 65.2 25.2 36.1 3.96
Fig. 3 Violin plot of the simulated hemoglobin level distributions pre-treatment and following 0.25 and 0.4 mg/kg primaquine for children 
< 5 years of age. The dashed lines represent the cut-offs between the different groups of anemia severity. This subgroup included 26% of the total 
individuals in the simulation dataset of which 6.5% were G6PD deficient
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to severe anemia decreased by 12%, 28% and 48% when 
excluding by pre-treatment hemoglobin < 7, 7.5 and 8 g/
dl, respectively (i.e. from 0.25 to 0.13% of the total popu-
lation for the 8 g/dl threshold). For 0.4 mg/kg primaquine, 
this proportion decreased by 10%, 22% and 41%, respec-
tively. After administering 0.4 mg/kg primaquine exclud-
ing individuals with pre-treatment hemoglobin < 8 g/dl, 
the prevalence of severe anemia was similar to that after 
treating everybody with 0.25 mg/kg primaquine.
Discussion
Concerns about primaquine safety related to hemoly-
sis have been an obstacle to its wide implementation as 
the risk is at the individual level while the benefit is only 
gained at the population level. Contemporary safety stud-
ies provide limited information at the population level as 
they are typically based on selected individuals with rela-
tively high pre-treatment hemoglobin. The present analy-
sis describes an assessment of the relationship between 
primaquine concentrations and primaquine-induced 
hemolysis in a semi-mechanistic model with the aim of 
exploring the safety of an MDA campaign with SLD-PQ 
in a sub-Saharan African setting. The analysis shows 
that, post treatment, hemoglobin levels would drop in a 
minority of individuals to levels below the pre-defined 
threshold defining (severe) anemia but that this effect is 
transient. G6PD-deficient individuals were found to be 
more at risk because of the increased hemolytic effect of 
primaquine.
The estimated pharmacokinetic parameters were simi-
lar between our model and the model built on the pedi-
atric data [18]. The erythrocyte lifespan was estimated at 
276 h, or 11.5 days, which is short compared to what is 
expected in healthy individuals (70–140 days) [36]. How-
ever, considering the facts that malaria infection itself 
drastically reduces erythrocyte lifespan (16–84  days) 
and that in individuals taking oxidative medication, 
like primaquine, the lifespan may even be shortened to 
2.5–5 days, we consider our findings in line with the lit-
erature [37, 38]. Although one may argue that our popu-
lation predictions for safety in a healthy population may 
not necessarily be representative as they are based on 
estimates from mostly malaria-infected patients of which 
many were G6PD deficient, we consider our predictions a 
“worst case scenario.”
The MDA simulations showed an increase in the preva-
lence of anemia (hemoglobin < 11–13  g/dl) after a sin-
gle dose of both 0.25  mg/kg and 0.4  mg/kg primaquine 
of 3.7% (8.6% relative increase) and 6.0% (14% relative 
increase), respectively. The increase in the prevalence 
of anemia was determined at nadir hemoglobin levels 
following primaquine treatment and was shown to be 
transient. After reaching the nadir following primaquine 
administration, the hemoglobin levels quickly recovered 
to return to baseline again after 25  days such that the 
reported increases in prevalence of anemia are present 
for a limited time [12, 39, 40]. The time to hemoglobin 
recovery was predicted to be independent of G6PD status 
or hemoglobin levels. The rapid recovery of hemoglobin 
levels also suggests that consecutive rounds of MDA with 
at least 1  month in between, as typically implemented 
[41, 42], would be unlikely to affect the prevalence of 
anemia.
Severe anemia is of most concern clinically, and whilst 
the relative increase in the prevalence of severe anemia 
was similar to that of any anemia grade in our Tanzanian 
setting, the absolute increase was much lower (0.25% vs 
3.7%). This suggests that post-SLD-PQ hemoglobin levels 
in a small but non-negligible number of individuals might 
drop below our severe anemia threshold of hemoglobin 
< 7–8  g/dl. Again, our predictions suggested this drop 
would be transient. Acknowledging that individuals with 
low hemoglobin are at higher risk of developing severe 
anemia, we investigated the exclusions of individuals 
with hemoglobin levels below specific thresholds. Chil-
dren < 5 years of age and women ≥ 15 years of age were 
most likely to have low hemoglobin levels in our simula-
tions and were most at risk to develop severe anemia. As 
expected, we predicted that the prevalence of individuals 
with severe anemia is reduced by not treating individu-
als with low pre-treatment hemoglobin levels (< 7, < 7.5 
or < 8  g/dl) although measuring hemoglobin on a large 
scale may be logistically challenging. Similarly, we pre-
dicted that by excluding individuals with hemoglobin val-
ues < 8 g/dl, 0.4 mg/kg primaquine can be used instead 
of 0.25 mg/kg without increasing the prevalence of severe 
anemia. Higher doses of SLD-PQ may be useful in the 
Table 5 Predicted prevalence of severe anemia after 0.25 
or 0.4 mg/kg primaquine per dosing scenario based on pre-
treatment hemoglobin level




Dosing all 0.25 2.98
0.40 3.14
Dosing Hb > 7.0 g/dl 0.25 2.95
0.40 3.10
Dosing Hb > 7.5 g/dl 0.25 2.91
0.40 3.03
Dosing Hb > 8.0 g/dl 0.25 2.86
0.40 2.97
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absence of specific low-dose or pediatric formulations of 
the drug.
It is important to acknowledge that we did not account 
for females who are heterozygous for G6PD deficiency 
genes as we did not have the data to do so. Heterozygous 
females have been described to present with a wide range 
of G6PD activity. In our analysis we decided to include 
the heterozygous females in the G6PD normal group as 
the majority will have a G6PD activity which is closer to 
normal than deficient activity [43, 44]. We performed a 
sensitivity analysis by simulating MDA in which het-
erozygous females were included in the G6PD-deficient 
group. In this simulation, 17.2% of the total population 
was defined to be G6PD deficient instead of 5.5% in the 
main analysis. The impact on the prevalence of anemia 
following SLD-PQ is generally negligible, e.g. the preva-
lence of severe anemia following 0.25 mg/kg primaquine 
increases from 2.98% to 3.02%. The full results of the sen-
sitivity analysis can be found in the supplementary mate-
rials (Additional file 9: Table S3).
The data used to develop the model did not include 
children < 2 years of age and our model does not include 
any enzymatic maturation factors on either the pharma-
cokinetics or pharmacodynamics. As MDA is recom-
mended to include children from the age of 6  months, 
the uncertainty in the extrapolation from our model to 
these younger children should be carefully considered. 
However, maturation of CYP2D6-dependent metabolism 
is not thought to play a role at this age [45], and recent 
findings support the safety of primaquine in young chil-
dren [46]. A further limitation is that this study included 
only individuals who were G6PD normal or G6PD defi-
cient with the African A- variant, the dominant variant 
in sub-Saharan Africa [29]. As the African A- variant is 
not the most severe variant of G6PD deficiency, this war-
rants caution for extrapolating to regions where more 
severe variants are prevalent. For example, individuals 
with the Mediterranean G6PD-deficiency variant have 
much lower G6PD enzyme activity compared to the 
African A- variant and subsequently are more at risk of 
severe hemolytic events. It should also be acknowledged 
that the Tanzanian dataset we used for MDA simulations 
may differ from other sub-Saharan African populations. 
For example, the simulation data were collected from vil-
lages at different altitudes, and whilst this encompasses 
a range of malaria endemicities, population hemoglobin 
levels will differ from other areas. As with other similar 
chemotherapeutic interventions, the epidemiology of 
malaria and co-infections would need to be considered 
in designing and implementing an MDA with SLD-PQ. 
Furthermore, our simulations were based on the likely 
availability of lower strength tablets produced at good 
manufacturing practice standards in the near future. 
These formulations are not currently available, and until 
then it will be more difficult to dose at the same precision 
as in our simulations. Lastly, it is important to emphasize 
that we have been cautious by using quite conservative 
definitions of anemia compared to other commonly used 
definitions, which further supports the safety of MDA 
with SLD-PQ in this population [47].
Conclusions
We predict a small drug concentration-dependent 
increase in hemolysis following primaquine administra-
tion, which disappears completely after 25  days. G6PD 
deficiency was associated with a 2.5-fold larger reduc-
tion in hemoglobin levels. MDA with SLD-PQ is pre-
dicted to result in a small and transient relative increase 
in the prevalence of anemia. Children < 5  years of age 
and women ≥ 15 years of age were found to have a higher 
chance to have low pre-treatment hemoglobin. Individu-
als with low pre-treatment hemoglobin are at increased 
risk of severe anemia but this is also expected to be tran-
sitory. By exclusion from dosing of individuals with low 
pre-treatment hemoglobin, the incidence of severe ane-
mia after SLD-PQ treatment could be limited. This study 
supports the feasibility of MDA with SLD-PQ in a sub-
Saharan African setting where anemia may be common.
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